about
Parkinsonism in spinocerebellar ataxiaWeight Change Is a Characteristic Non-Motor Symptom in Drug-Naïve Parkinson's Disease Patients with Non-Tremor Dominant Subtype: A Nation-Wide Observational StudyUnusual epileptic deterioration and extensive white matter lesion during treatment in Wilson's disease.Amantadine induced corneal edema in a patient with primary progressive freezing of gaitA case of adrenoleukodystrophy presenting as progressive cerebellar dysfunction.Stiff-person syndrome: case series.Overnight switch from ropinirole to transdermal rotigotine patch in patients with Parkinson diseaseNanomolar concentration of alpha-synuclein enhances dopaminergic neuronal survival via Akt pathway.Influence of propofol and fentanyl on deep brain stimulation of the subthalamic nucleus.Intravenous amantadine for freezing of gait resistant to dopaminergic therapy: a randomized, double-blind, placebo-controlled, cross-over clinical trial.Hypothesis: somatic mosaicism and Parkinson diseaseComparison of once-daily versus twice-daily combination of ropinirole prolonged release in Parkinson's disease.Identifying the clusters within nonmotor manifestations in early Parkinson's disease by using unsupervised cluster analysis.Dysport and Botox at a ratio of 2.5:1 units in cervical dystonia: a double-blind, randomized study.Electrode position and the clinical outcome after bilateral subthalamic nucleus stimulationNonmotor Symptoms and Subthalamic Deep Brain Stimulation in Parkinson's Disease.The Pathogenic Role of Low Range Repeats in SCA17.Long-Term Clinical Outcome of Internal Globus Pallidus Deep Brain Stimulation for DystoniaSudden loss of the deep brain stimulation effect with high impedance without macroscopic fracture: a case report and review of the published literatureBilateral Deep Brain Stimulation of the Subthalamic Nucleus under Sedation with Propofol and Fentanyl.Dural Arteriovenous Fistula-Associated Reversible Parkinsonism with Presynaptic Dopaminergic LossSwitching from an oral dopamine receptor agonist to rotigotine transdermal patch: a review of clinical data with a focus on patient perspective.Alpha-Synuclein Expression in Patients with Parkinson's Disease: A Clinician's Perspective.Intravenous recombinant tissue plasminogen activator thrombolysis in a patient with acute ischemic stroke secondary to aortic dissection.Acute subdural hematoma following spinal cerebrospinal fluid drainage in a patient with freezing of gait.Survival of Korean Huntington's Disease Patients.Pregnancy and Delivery in a Generalized Dystonia Patient Treated with Internal Globus Pallidal Deep Brain Stimulation: a Case Report.Mitochondrial dysfunction of immortalized human adipose tissue-derived mesenchymal stromal cells from patients with Parkinson's disease.Validation of the Korean Version of the Scale for Outcomes in Parkinson's Disease-Autonomic.Survival of Korean patients with multiple system atrophy.Effect of deep brain stimulation on pain in Parkinson disease.Diagnosis and differential diagnosis of MSA: boundary issues.Multiple system atrophy-mimicking conditions: Diagnostic challenges.Psychiatric symptoms in myoclonus-dystonia syndrome are just concomitant features regardless of the SGCE gene mutation.Liquid levodopa-carbidopa in advanced Parkinson's disease with motor complications.Putaminal serotonergic innervation: monitoring dyskinesia risk in Parkinson disease.Two-year follow-up on the effect of unilateral subthalamic deep brain stimulation in highly asymmetric Parkinson's disease.Increased expression of α-synuclein by SNCA duplication is associated with resistance to toxic stimuli.MRI-Based Attenuation Correction for PET/MRI Using Multiphase Level-Set Method.An 8-Year Follow-up on the Effect of Subthalamic Nucleus Deep Brain Stimulation on Pain in Parkinson Disease.
P50
Q28080641-8BA9BBE2-720B-45A2-A767-79377657BA4CQ28554041-226A80C7-1AD8-47AA-9455-126F5AB0576CQ30558701-95CA6589-98A6-4082-811E-450CE9B0F14BQ33636215-DAF9EAF9-3EBA-4655-ABC0-B642146B396FQ33636422-E496EA6E-C353-4E1F-905A-0DB5F0E67862Q33734422-ED6F8248-8A2C-404B-B394-F0BCFB2B1F07Q33989482-0E39B30B-7D71-4A1A-B32F-13CE8B992B55Q34094699-A8C9E20E-96C7-4EF9-8165-0F5F7E4CF39AQ34208352-5BFDF245-C2D2-4DC7-BEED-3DA8E11070BFQ34489770-E16B5213-6492-4B58-9325-595C7C1CB298Q34774314-86D1A7E7-8597-49AF-93B6-101F4DF0FCF0Q34978119-F30E374C-7A09-4BE5-A90F-B221AC08E9E0Q35124218-441B77CA-69E1-4F93-8852-02EDA9B5FE6AQ35175351-0ADFD77B-06F9-4ED4-AF92-302E9C7AFE81Q35333872-699C7935-3BA7-4EBD-AF7A-38B9ADA2A38EQ35699789-0C4CDB23-C38C-4C6F-B49A-359948731EFDQ35743770-3F809ED0-0DEC-44C4-BED7-8C0B1FDA9E89Q35888830-39815011-C086-46AC-87B0-A220623CBA2BQ35892873-0461CFD2-B4FE-43D2-9880-DD56DCCD99C1Q35971349-0546DCB0-5D45-482E-B103-C55BFFBC2D3EQ36067233-6377CB71-E6C0-48F7-90A9-43C5D2E0833CQ36382845-DAD468A2-A78A-4D11-883D-190407143908Q36976868-B93C884F-FA1C-4909-BF95-79CDAE73AC1BQ37203364-1B690B69-A073-4ACE-B4DE-512FCC50F948Q37252158-B6EAAEE3-D73A-40BD-BF61-7CEEC358C98EQ37281724-EC937957-A241-481D-A2D2-61DB12DD7343Q37482426-DF0E8CBD-4388-4CDB-BC6D-CBBE0608B525Q37500329-5FF58641-CCFB-4364-A610-265A276367B0Q37620458-A0C0F4C4-AC40-48F6-8319-B6E1478E1FD3Q37834518-8F761BA1-13BB-461F-B6B3-7A0AFC009C1AQ37894949-7467BE66-AA49-4A3D-B0DC-4669D595AAF6Q38348584-2153A6C3-20DB-454C-B8A9-3C891EE278E2Q38586159-387062FF-CAA4-4003-B496-D589CF8794CCQ38687672-2DB3B21E-968F-4A41-9AC9-1B305B69BCF6Q38800761-48376E5D-93EB-44F6-8B9C-BE3BCF711805Q38976529-2266E70D-2557-405E-B085-6ECD61783875Q39311976-45652BC5-95E4-44A9-9555-F28A1481377BQ39385017-D018F7DD-0CD3-4179-B6D6-8274D841375DQ40177771-8ECD8E3C-393C-47CF-BE24-A4E0BEB38DE5Q41177829-7463A1B5-FD37-4345-AFD5-A97E1DAAA67C
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Han-Joon Kim
@ast
Han-Joon Kim
@en
Han-Joon Kim
@es
Han-Joon Kim
@nl
type
label
Han-Joon Kim
@ast
Han-Joon Kim
@en
Han-Joon Kim
@es
Han-Joon Kim
@nl
prefLabel
Han-Joon Kim
@ast
Han-Joon Kim
@en
Han-Joon Kim
@es
Han-Joon Kim
@nl
P106
P1153
36067006300
P214
1350148753680741320005
P31
P496
0000-0001-8219-9663
P7859
viaf-1350148753680741320005